The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.1
STANDARD TREATMENT – Recently updated guidelines recommend that antiretroviral-naive patients infected with HIV-1 receive an INSTI-based regimen or a regimen including the protease inhibitor (PI) darunavir boosted with ritonavir (see Table 1). Because the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and the PI atazanavir have been...
- Drugs for Acne
- Drugs for Rosacea
- Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
- Addendum: Timing of Levothyroxine
The FDA has approved selexipag (Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram), an oral prostacyclin analog, was approved earlier for this indication.
STANDARD TREATMENT — Monotherapy with an oral drug is usually recommended for initial treatment of PAH (WHO functional class II or III). Drugs approved by the FDA for this indication include phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists, and a guanylate cyclase ...